Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Stories

Sac-TMT extends survival over chemotherapy in EGFR-mutant lung cancer

Developer of sac-TMT; presented final OptiTROP-Lung04 survival data and first-line OptiTROP-Lung06 results at ESMO 2026

Patients with EGFR-mutant lung cancer whose disease progressed on targeted therapy lived a median 25.9 months on sac-TMT, against 17.4 months on platinum doublet chemotherapy. Those are the final overall survival figures from the 376-patient OptiTROP-Lung04 trial, presented at the 2026 ESMO Congress in Madrid by Wenfeng Fang of Sun Yat-sen University Cancer Center.

Updated Oct 27

Antibody-drug conjugate combination outperforms chemo-immunotherapy in PD-L1-negative lung cancer

New Capabilities

Sponsor of OptiTROP-Lung06 and developer of sac-TMT

Pairing an antibody-drug conjugate with pembrolizumab kept advanced lung cancer from worsening for a median of 15 months, nearly three times as long as the standard pembrolizumab-plus-chemotherapy regimen. The Phase III OptiTROP-Lung06 results were presented on October 25 at the ESMO congress in Madrid and published the same day in the New England Journal of Medicine.

Updated Oct 27